Aerosolized antibiotics in cystic fibrosis: An update

Expert Review of Respiratory Medicine

Volumn 8, Issue 3, 2014, Pages 305-314

  Fiel, Stanley B ^a  

^a Atlantic Health   (United States)

Author keywords

aerosolized antibiotic; aztreonam lysine; colistimethate sodium; cystic fibrosis; dry powder for inhalation; inhaled solution; Pseudomonas aeruginosa; tobramycin

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM LYSINE; CIPROFLOXACIN; COLISTIMETHATE; TOBRAMYCIN; AMIKACIN; ANTIINFECTIVE AGENT; AZTREONAM; COLISTIN; COLISTINMETHANESULFONIC ACID; LEVOFLOXACIN;

AEROSOL; ANTIBIOTIC THERAPY; CYSTIC FIBROSIS; DRUG FORMULATION; DRY POWDER INHALER; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MULTICENTER STUDY (TOPIC); PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; DRUG EFFECTS; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; NEBULIZER; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; AMIKACIN; ANTI-BACTERIAL AGENTS; AZTREONAM; COLISTIN; CYSTIC FIBROSIS; EQUIPMENT DESIGN; HUMANS; LEVOFLOXACIN; NEBULIZERS AND VAPORIZERS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOBRAMYCIN;

EID: 84901068785     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.896205     Document Type: Review

References (42)

1. Flume PA. Pulmonary complications of cystic fibrosis. Respir Care 2009;54(5): 618-27
2. Cystic Fibrosis Foundation Patient Registry. 2011 annual data report. Cystic Fibrosis Foundation; Bethesda, MD, USA
3. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180(9):802-8
4. Fiel SB. Aerosolized antibiotics in cystic fibrosis: current and future trends. Expert Rev Respir Med 2008;2(4):479-87
5. Vandevanter DR, Geller DE. Tobramycin administered by the TOBI Podhaler for persons with cystic fibrosis: a review. Med Devices (Auckl) 2011;4:179-88
6. Rose LM, Neale R. Development of the first inhaled antibiotic for the treatment of cystic fibrosis. Sci Transl Med 2010;2(63): 63mr64
7. Novartis Pharmaceuticals Corporation, TOBI. (tobramycin inhalation solution) [prescribing information and patient prescribing information]. Novartis Pharmaceuticals Corporation; East Hanover, NJ, USA 2009
8. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-9
9. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30
10. Ratjen F, Munck A, Kho P, Angyalosi G; Elite Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65(4):286-91
11. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165(9):847-56
12. Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012;47(1):44-52
13. Coates AL, Denk O, Leung K, et al. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatr Pulmonol 2011;46(4):401-8
14. Lenney W, Edenborough F, Kho P, Kovarik JM. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros 2011;10(1):9-14
15. Hubert D, Leroy S, Nove-Josserand R, et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J Cyst Fibros 2009;8(5):332-7
16. Gilead Sciences, Inc., CAYSTON (aztreonam for inhalation solution) [prescribing information]. Gilead Sciences, Inc; Foster City, CA, USA, 2012
17. Plosker GL. Aztreonam lysine for inhalation solution: in cystic fibrosis. Drugs 2010; 70(14):1843-55
18. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135(5):1223-32
19. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178(9):921-8
20. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013;12:130-40
21. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45(11):1121-34
22. Novartis Pharmaceuticals Corporation, TOBI PODHALER (tobramycin inhalation powder) [prescribing information]. Novartis Pharmaceuticals Corporation; East Hanover, NJ, USA: 2013
23. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv 2011; 24(4): 175-82
24. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10(1):54-61
25. Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011; 46(3):230-8
26. Galeva I, Konstan MW, Higgins M, et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr Med Res Opin 2013;29(8):947-56
27. Harrison MJ, Mccarthy M, Fleming C, et al. Improved tolerability, adherence and reduced intravenous (IV) antibiotic usage in CF patients receiving inhaled versus nebulised antibiotic prophylaxis. A real world comparison of tobramycin inhaled powder (TIP) and tobramycin inhaled solution (TIS). J Cyst Fibros 2013; 12(Suppl 1):S67. Abstract 74
28. Schuster A, Haliburn C, Döring G, Goldman MH; Freedom Study Group. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68(4):344-50
29. Stass H, Nagelschmitz J, Willmann S, et al. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Investig 2013;33(6): 419-27
30. Sabet M, Miller CE, Nolan TG, et al. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53(9):3923-8
31. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183(11):1510-16
32. Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013;68(9):818-25
33. Noah TL, Ivins SS, Abode KA, et al. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol 2010;45(3):281-90
34. Proesmans M, Vermeulen F, Boulanger L, et al. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2013;12(1):29-34
35. Taccetti G, Bianchini E, Cariani L, et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 2012;67(10):853-9
36. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012;185(2):171-8
37. Herrmann G, Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 2010;202(10):1585-92
38. Berlana D, Llop JM, Manresa F, Jódar R. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. Pharmacotherapy 2011;31(2):146-57
39. Tré-Hardy M, Nagant C, El Manssouri N, et al. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother 2010;54(10):4409-15
40. Tré-Hardy M, Traore H, El Manssouri N, et al. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2009;34(4):370-4
41. Pilcer G, Rosière R, Traina K, et al. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J Pharm Sci 2013;102(6): 1836-46
42. Zeitler K, Salvas B, Stevens V, Brown J. Aztreonam lysine for inhalation: new formulation of an old antibiotic. Am J Health Syst Pharm 2012;69(2):107-15